Business Context and Reporting Period
Company: Alkermes Plc.
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Overview: Alkermes is a global biopharmaceutical company focused on neuroscience, developing medicines for alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder. The company operates as a single segment and is headquartered in Ireland with significant operations in the U.S.
Key Financial Metrics
| Metric | 2024 (in millions) | 2023 (in millions) |
|---|---|---|
| Total Revenues | $1,557.6 | $1,663.4 |
| Net Income (Continuing Ops) | $372.1 | $519.2 |
| Net Income (Total) | $367.1 | $355.8 |
| Operating Income | $420.6 | $414.1 |
| Operating Cash Flow | $439.1 | $401.4 |
| Cash & Investments | $824.7 | $813.4 |
| Long-Term Debt | $0.0 | $287.7 |
| Effective Tax Rate | 16.1% | (23.2)% |
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased by approximately 6.4% to $1.56 billion. This was primarily driven by a significant drop in royalty revenues from long-acting INVEGA products ($236.5M in 2024 vs. $486.1M in 2023). The 2023 figure included a one-time receipt of $195.4 million in back royalties and interest following a successful arbitration with Janssen. Additionally, the royalty on U.S. net sales of INVEGA SUSTENNA expired in August 2024.
- Product Sales Growth: Net product sales increased by 17.8% to $1.08 billion. Notable growth was seen in LYBALVI (+45.9%), driven by a 45% increase in units sold. VIVITROL and ARISTADA also saw modest growth.
- Profitability: Net income from continuing operations decreased by 28.3% to $372.1 million. The decline is largely attributed to the absence of the one-time back royalty payment and tax benefit from the release of valuation allowances that occurred in 2023.
- Debt Elimination: In December 2024, the company prepaid all outstanding term loans ($289.5 million), resulting in zero long-term debt as of year-end.
- Asset Sale: In May 2024, the company sold its Athlone Facility and related business to Novo Nordisk for $97.9 million, recording a gain of approximately $1.5 million.
Guidance, Outlook, and Risks
- Outlook: Management expects royalty revenues from long-acting INVEGA products to decrease further in 2025 as the royalty on U.S. net sales of INVEGA SUSTENNA has expired. The company anticipates existing cash and investments will be sufficient to finance operations for at least the next 12 months.
- Development Pipeline: The company is advancing ALKS 2680, an investigational oral treatment for narcolepsy and idiopathic hypersomnia, with Phase 2 studies ongoing and a third study expected to initiate in the first half of 2025.
- Key Risks:
- Patent Expirations: VIVITROL faces generic competition starting January 2027 under settlement agreements with Teva and Amneal. RISPERDAL CONSTA patents have expired in the U.S. and EU, leading to declining revenues.
- Regulatory & Legal: Ongoing government investigations regarding VIVITROL and patent litigation (e.g., INVEGA TRINZA, VUMERITY) pose risks to future revenue streams.
- Manufacturing Concentration: The company relies on a single manufacturing facility in Wilmington, Ohio, for key proprietary products (VIVITROL, ARISTADA, LYBALVI).
- Tax Uncertainty: Risks exist regarding the tax-free status of the 2023 oncology business separation and the realization of deferred tax assets.
Investor Verification Checklist
- INVEGA Royalty Trajectory: Verify the specific timeline and revenue impact of the expiration of the INVEGA SUSTENNA royalty in August 2024 and the remaining royalty terms for INVEGA TRINZA and HAFYERA.
- VIVITROL Generic Entry: Confirm the details of the settlement agreements with Teva and Amneal regarding the January 2027 generic entry date and potential earlier entry clauses.
- Debt-Free Status: Confirm the terms of the debt prepayment in December 2024 and ensure no hidden covenants or future financing needs are disclosed.
- Athlone Facility Transition: Review the subcontracting arrangements with Novo Nordisk for VUMERITY manufacturing to ensure supply continuity through the end of 2025.
- Deferred Tax Assets: Assess the valuation allowance against Irish and U.S. deferred tax assets, particularly given the abandonment of certain Irish NOLs following the Athlone sale.